AIM
PTCT icon

AXA Investment Managers’s PTC Therapeutics PTCT Stock Holding History

AXA Investment Managers’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$2.49M Buy
+40,500
New +$2.11M 0.01% 732

Other funds holding PTCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

AXA Investment Managers's PTCT Position: Q3 2025 in Review

AXA Investment Managers opened a new position in PTC Therapeutics (PTCT) in Q3 2025: 40,500 shares worth $2.49M. The stake represents 0.01% of the portfolio and ranks #732 among its holdings.

293 funds tracked by Wall St. Rank hold PTCT as of Q3 2025.

  • AXA Investment Managers held 40,500 shares of PTC Therapeutics worth $2.49M as of Q3 2025.
  • PTC Therapeutics was a new AXA Investment Managers position in Q3 2025.
  • PTC Therapeutics made up 0.01% of AXA Investment Managers's portfolio in Q3 2025, its #732 holding.
  • 293 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2025.

Based on AXA Investment Managers's 13F filing for Q3 2025, filed 14 Nov 2025.